ARTEMIS - The ARTEMIS Cohort

This multinational European observational clinical study focuses on non-progressive congenital ataxia (NPCA), a very rare early-onset neurological condition also within the cerebral palsy (CP) concept as ataxic CP. The study aims to improve the diagnosis and care of affected children through a comprehensive approach that integrates detailed clinical assessments, brain imaging analyses, and advanced genetic testing. By identifying developmental trajectories, specific impairment profiles, brain MRI patterns, and genetic variants, the researchers aim to elucidate underlying mechanisms, origins and clinical heterogeneity of NPCA. The study also assesses the broader impact of the condition on the quality of life of affected children and the associated burden on their families. Preliminary data found a high prevalence of cognitive and neuropsychiatric impairments, and a frequent lack of identifiable brain lesions on MRI, raising the hypothesis of a strong genetic contribution.

NCT Number	NCT07421219
Lead Sponsor	Vastra Gotaland Region Collaborators: University Hospital, Toulouse, Universität Tübingen, University Hospital Tuebingen, Sykehuset i Vestfold Hospital Trust, Aarhus University Hospital, KU Leuven, Sahlgrenska University Hospital, Göteborg University, IASO Children's Hospital, Maroussi, Athens, Greece
Conditions	Non-progressive Congenital Ataxia, Ataxic Cerebral Palsy
Enrollment	50 participants
Start Date	2026-04
Primary Completion	2027-10 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-02-19